Edition:
India

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

3.52USD
15 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.52
Open
$3.28
Day's High
$3.55
Day's Low
$3.28
Volume
44,180
Avg. Vol
96,115
52-wk High
$8.88
52-wk Low
$2.42

Summary

Name Age Since Current Position

Wei-Wu He

53 2018 Executive Chairman of the Board

Ken Ren

59 2014 Chief Executive Officer, Director

George Chi

52 2018 Chief Financial Officer

Cynthia Hu

48 2008 Chief Operating Officer, General Counsel, Secretary

Sara Capitelli

51 2011 Vice President - Finance, Principal Accounting Officer

Rong Chen

2015 Chief Medical Officer

Tak Mak

71 2012 Director

Rajesh Shrotriya

74 2014 Director

James Huang

52 2013 Independent Director

Franklin Salisbury

62 2014 Independent Director

Y. Alexander Wu

54 2013 Independent Director

Biographies

Name Description

Wei-Wu He

Dr. Wei-Wu He, Ph.D., is Executive Chairman of the Board of the Company. Dr. He has served as Executive Chairman of the Company since February 23, 2018. Dr. He served as Chairman of the Company from May 2013 to February 23, 2018, and as Executive Chairman from February 2012 to May 2013. Dr. He has served as the Chief Executive Officer and Chairman of OriGene Technologies, Inc. since 1995. He also is the founder and General Partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania. We believe that as a seasoned leader in the biotechnology industry and demonstrated financing and business acumen in both the United States and China, Dr. He adds valuable insight and expertise to the Board of Directors. Dr. He’s knowledge of the drug development process provides valuable insight to the Company. His leadership skills, strategic analysis, industry knowledge and substantial experience in the biotech sector give him the qualifications and skills to serve as a director and the Executive Chairman of the Company.

Ken Ren

Dr. Ken K. Ren, Ph.D., is Chief Executive Officer, Director of the Company. Dr. Ren joined the Company in April 2012 as interim Chief Executive Officer, and after successful completion of the one-year interim period, was appointed Chief Executive Officer in April 2013, and in December 2014 was elected to the Board of Directors. Prior to joining the Company, from 2005-2012, Dr. Ren was the president of Accelovance (China), a subsidiary of Accelovance, Inc., which is a Maryland-based contract research organization. Prior to Accelovance, Dr. Ren was the founder of New Jersey-based AHT Inc., which merged with Novemed, a portfolio investment of a blue-chip public company in Hong Kong. He was a co-founder of the China Innovation Center for Life Science (U.S.A.) Corp., a New York-based consulting firm in partnership with the Chinese Ministry of Science and Technology which provided consulting services to health-care and pharmaceutical companies in both the U.S. and China. Over the past 15 years Dr. Ren has been involved in several U.S./China based start-up companies in pharmaceutical development or services. Dr. Ren was a research scientist at Pfizer from 1993–1995 and a Research Fellow at Rockefeller University from 1990–1993. He received his medical degree at the Shandong University School of Medicine in China in 1986 and a Ph.D. from State University of New York at Buffalo in 1990. Dr. Ren’s qualifications to serve on the Board of Directors include his extensive leadership experience and background in the healthcare and pharmaceutical industries, which make him well qualified to serve on our Board of Directors.

George Chi

Mr. George Chi is Chief Financial Officer of the Company. He was the Vice President of Finance of Flavors Holdings from 2016 until his appointment by the Company. From 2014-2016, he was CFO of BPL Plasma, and from 2008-2013, he was Finance Director of Unilever. Mr. Chi received his MBA in Finance and Operations Management from the Yale School of Management in 2003 and his Bachelor of Engineering from Tsinghua University in Beijing, China in 1993.

Cynthia Hu

Ms. Cynthia W. Hu, J.D., is Chief Operating Officer, General Counsel, Secretary of the Company. Ms. Hu joined the Company in June 2006 as Vice President, General Counsel & Secretary and was appointed Chief Operating Officer in December 2008. Prior to joining the Company, from January 2000 to May 2006, Ms. Hu served as senior attorney for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, Ms. Hu served as corporate and securities counsel for a NYSE-listed financial institution and prior to that was in private practice with increasing levels of responsibilities, including at the law firms of Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on public corporate transactions, financings, mergers and acquisitions, and compliance with corporate and securities laws. Ms. Hu received her juris doctorate degree from Rutgers University in 1995, and her bachelor’s degree from New York University in 1991.

Sara Capitelli

Ms. Sara B. Capitelli, CPA, serves as Vice President - Finance, Principal Accounting Officer of the Company. Ms. Capitelli joined the Company in January 2011 as Vice President, Finance and Principal Accounting Officer. Prior to joining the Company, from May 2010 to January 2011, Ms. Capitelli served as Controller for the Association for Financial Professionals in Bethesda, Maryland. From 1999-2008, Ms. Capitelli served as Senior Manager with Ernst & Young LLP, where she provided audit and consulting services for small and large public and private companies. Prior to that, she served as Director, Financial Planning and Reporting of Cable & Wireless USA, a wholly-owned subsidiary of Cable & Wireless plc. Ms. Capitelli holds a CPA license in both Maryland and Virginia. Ms. Capitelli received her Bachelor of Science, Business Administration – Accounting, from Bucknell University in 1988.

Rong Chen

Dr. Rong Chen M.D., Ph.D. is Chief Medical Officer of the Company. Prior to joining CASI, Dr. Chen was Area Medical Director and Chief Medical Governance Officer at GSK China/ Hong Kong Area and in 2010 was promoted to VP, Head of Regulatory Center of Excellence, Company Representative having overall responsibility for the registration of drug and vaccine products. Prior to GSK, he was Medical Director, Global Medical Expert at Bayer-Schering Pharma Asia Pacific Area and from 2001-2005 was Medical Director at Sanofi China. Dr. Chen was co-author of various published articles and has presented at many international conferences. Dr. Chen received his medical degree from Shandong Medical University, China and received his Ph.D. in Clinical Pharmacology from the Royal Adelaide Hospital, University of Adelaide, Australia in 1989.

Tak Mak

Dr. Tak W. Mak, Ph.D., serves as Director of the Company. He has been the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital since 2004 and a University Professor in the Department of Medical Biophysics and Department of Immunology, University of Toronto, since 1984 and Professor in the Department of Medicine, University of Toronto, since 2008. Dr. Mak’s vast career includes serving as Vice President of Research at Amgen, Inc. and Director of the Amgen Institute in Toronto from 1993-2002, and is best known as the leading scientist of the group that first cloned the genes of the human T cell antigen receptor. Dr. Mak is an Officer of the Order of Canada, and has been elected a Foreign Associate of the National Academy of Sciences (USA), a Foreign Associate of the American Academy of Arts and Sciences, as well as a Fellow of the Royal Society of London (UK). He was awarded the Order of Ontario and has won international recognition in the form of the Emil von Behring Prize, the King Faisal Prize for Medicine, the Gairdner Foundation International Award, the Sloan Prize of the General Motors Cancer Foundation, the Novartis Prize in Immunology and the Paul Ehrlich Prize and Ludwig Darmstaedter Prize of Germany. Dr. Mak’s past and current ground-breaking medical research and his significant experience as a leader in pharmaceutical companies and research institutes provides significant insight in helping the Board of Directors formulate corporate strategies impacting the Company’s science, research and clinical development.

Rajesh Shrotriya

Dr. Rajesh C. Shrotriya is Director of the Company, effective September 22, 2014. Dr. Shrotriya has been a director of the Company since September 2014. From 2000 – 2017, he was President and Chief Operating Officer and Chief Executive Officer of Spectrum Pharmaceuticals. In this capacity he spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc. where he continues to be a Director of the company. He is also a Director of the UNVL Foundation. Prior to joining Spectrum, from September 2000 to August 2002, Dr. Shrotriya was President and COO of Neotherapeutics, Inc., and prior to that he was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research. Dr. Shrotriya’s significant leadership experience in the biopharmaceutical sector, along with his experience as a physician and his expertise in drug development, make him well-qualified to serve on our Board of Directors.

James Huang

Mr. James Z. Huang is an Independent Director of the Company. Mr. Huang has been a Director of the Company since April 2013. Mr. Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007. Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Meanwhile, James Huang is also funding and manager partner to Panacea Venture, Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide, is established and managed by experienced partners Mr. James Huang and Dr. Hai Mi, both of whom are KPCB China’s managing partner and partner, respectively. James is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals. James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

Franklin Salisbury

Mr. Franklin C. Salisbury, Jr., is an Independent Director of the Company. Since 1998, Mr. Salisbury has been a Director of the Company since June 2014. Since 1998, Mr. Salisbury has been President of the National Foundation for Cancer Research (NFCR), an organization that supports healthcare companies and research institutions in order to accelerate new approaches to preventing, diagnosing and treating cancer. Under his leadership, NFCR has forged greater collaboration among scientists at universities, research hospitals and pharmaceutical companies in the U.S. and China in an effort to bring new and innovative care to cancer patients. Mr. Salisbury also led NFCR to launch several research consortia that have enabled cancer researchers to pool their resources and reduce duplicative efforts, thereby accelerating discoveries being made and reducing the cost of achieving them. Mr. Salisbury holds a B.A. in economics from Yale, a Juris Doctor, J.D., from the University of Georgia School of Law, a Masters of Arts degree from the University of Chicago, and a M.Div. from Yale Divinity School. Mr. Salisbury’s leadership experience and significant background in supporting cancer research give him the qualification and skills necessary to guide the Company’s Board of Directors, including as a member of the Compensation Committee and Audit Committee.

Y. Alexander Wu

Dr. Y. Alexander Wu, Ph.D., is an Independent Director of the Company. Dr. Wu has been a Director of the Company since April 2013. From 2006 to 2017, Dr. Wu was co-founder and Chief Executive Officer of Crown Bioscience, Inc., a drug discovery and preclinical research organization in the oncology sector with over 600 employees. The company was acquired by JSR for over $400 million in 2017. Before co-founding Crown Bioscience, Dr. Wu was Chief Business Officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the Head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was Chief Operating Officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was Manager of Business Development and Strategic Planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in Biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley. Dr. Wu’s experience in the biopharmaceutical industry and research in the oncology and small molecule areas, practical experience as a senior executive operating in U.S. and China, and entrepreneurial vision makes him uniquely qualified to serve as a Director, as well as a member of the Compensation Committee and Audit Committee.

Basic Compensation

Name Fiscal Year Total

Wei-Wu He

121,000

Ken Ren

788,415

George Chi

--

Cynthia Hu

467,099

Sara Capitelli

292,803

Rong Chen

--

Tak Mak

--

Rajesh Shrotriya

43,100

James Huang

56,750

Franklin Salisbury

43,100

Y. Alexander Wu

--
As Of  31 Dec 2017